Summary
Our team
Director of Marketing & Communication
Key Account Manager
Talk
Supporting Viral vector therapies from PD to Commercialization
The gene therapy industry is currently witnessing an unprecedented growth rate. Despite the rapid growth of the industry, several limitations remain with regarding the robust manufacture of viral vectors and the ability to efficiently produce increasingly larger volumes of finished product. Transient transfection of suspension cells is the most commonly used production platform for AAV manufacturing. However, this method shows some limitations for commercialization: inadequate transfection protocol, reduced transfection efficiency and lower productivity. To address this concern, we present data on Polyplus-transfection novel transfection reagent FectoVIR®-AAV showing: i) increased AAV titers, ii) improved transfection protocol for large scale bioreactors and iii) reproducibility of viral titers at different production scale.
Presented by Géraldine GUERIN-PEYROU, Director of Marketing & Communication at Polyplus-transfection®
Talk available on demand.
Our solutions for both protein and virus production
FectoVIR®-AAV: for Recombinant AAV virus production in suspension cells.
PEIpro® product range for a scalable viral vector production for Gene & Cell therapy.
FectoPRO® Transfection kit is specifically designed for enhanced Transient Gene Expression (TGE) in suspension CHO and HEK-293 cells in various serum-free media, using low DNA amount (< 1 µg/ml of cell culture).